Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2017, the company operated 74 imaging centers located in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, arthrography, and other diagnostic or interventional radiology procedures; and medical billing services. Akumin Inc. is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone416-613-1391
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$215.86 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable
Akumin (TSE:AKU) Frequently Asked Questions
What is Akumin's stock symbol?
Akumin trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AKU."
How were Akumin's earnings last quarter?
Akumin Inc (TSE:AKU) released its quarterly earnings results on Thursday, November, 14th. The company reported $0.08 earnings per share for the quarter, hitting analysts' consensus estimates of $0.08. The firm earned $90.93 million during the quarter, compared to analyst estimates of $88.65 million. View Akumin's Earnings History.
When is Akumin's next earnings date?
Has Akumin been receiving favorable news coverage?
News articles about AKU stock have trended somewhat negative recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akumin earned a coverage optimism score of -1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Akumin.
Who are some of Akumin's key competitors?
Some companies that are related to Akumin include Integral Diagnostics (IDX), Volpara Health Tech (VHT), Exagen (XGN), Senseonics (SENS), Renalytix Ai (RENX), Palatin Technologies (PTN), Profound Medical (PRN), Oncosil Medical (OSL), Yourgene Health (YGEN), MaxCyte (MXCT), Lexagene (LXG), BARD1 Life Sciences (BD1), Sernova (SVA), Oncimmune (ONC) and GeneNews (GEN).
What other stocks do shareholders of Akumin own?
Who are Akumin's key executives?
Akumin's management team includes the folowing people:
- Mr. Riadh Zine-El-Abidine, Pres, CEO & Director (Age 47)
- Mr. Mohammad Saleem, CFO & Corp. Sec.
- Mr. Rohit Navani, Exec. VP & COO
- Mrs. Amy Adams MBA, Sr. VP of Clinical Devel.
- Ms. Laura Kassa, Sr. VP of Operations of Akumin Corp.
How do I buy shares of Akumin?
Shares of AKU and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Akumin's stock price today?
One share of AKU stock can currently be purchased for approximately C$5.12.
How big of a company is Akumin?
What is Akumin's official website?
How can I contact Akumin?
The company can be reached via phone at 416-613-1391.
MarketBeat Community Rating for Akumin (TSE AKU)
MarketBeat's community ratings are surveys of what our community members think about Akumin and other stocks. Vote "Outperform" if you believe AKU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKU will underperform the S&P 500 over the long term. You may vote once every thirty days.
